Trial Profile
Phase I trial of VX-787 in healthy volunteers.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Sep 2020
Price :
$35
*
At a glance
- Drugs Pimodivir (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- 02 Sep 2020 According to a Janssen media release, company discontinued development of pimodivir for the treatment of influenza A infection. This decision is based on results from pre-planned interim analyses of the pimodivir phase III trial in hospitalized patients with influenza A. Pimodivir in combination with the standard of care (SOC) fails to demonstrate added benefit in hospitalized patients with influenza A compared to SOC treatment alone.
- 02 Sep 2020 Status changed from recruiting to discontinued, according to a Janssen media release.
- 28 Oct 2011 Status changed from planning to recruiting.